Table 3.

HCV Direct-Acting Antiviral Drug Classes and US FDA Approval Status

HCV Direct-Acting Antiviral Class	Drug (year/status of US FDA approval)
NS3 Protease inhibitors	Simeprevir (2013) Paritaprevir/ritonavir (2014) Asunaprevir (not approved)
NS5B Nucleos(t)ide poly- merase inhibitor	Sofosbuvir (2013)
NS5B Nonnucleoside polymerase inhibitors	Dasabuvir (2014) Beclabuvir (not approved)
NS5A Inhibitors	Ledipasvir (2014) Ombitasvir (2014) Daclatasvir (not approved)

Abbreviations: HCV, hepatitis C virus; NS, nonstructural protein; US FDA, US Food and Drug Administration.